OVERVIEW

Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva is organized by Rockpointe Corporation, Potomac Center for Medical Education (PCME)

Release Date: Oct 01, 2020
Expiration Date: Oct 01, 2021

Accreditation:
The Potomac Center for Medical Education designates this enduring materials for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program.

Program Overview:
As a rare disease, fibrodysplasia ossificans progressiva (FOP) poses substantial diagnostic and treatment challenges for pediatricians and pediatric orthopedists. It is frequently confused with other development bone diseases due to similar presentation, and treatment options are lacking. Currently, treatment of FOP is limited to symptomatic management of disease flare-ups. In recent years, however, improved understanding of the genetics and pathophysiology of FOP have led to improvements in diagnosis and treatment, as well as the identification of multiple new therapeutic targets. Novel agents that have demonstrated efficacy in minimizing disease symptoms and slowing progression of disease are currently in late-stage clinical trials and may soon be available for FOP treatment.

This activity, Hardened Hope: Care Advances for Patients with Fibrodysplasia Ossificans Progressiva, will provide clinicians with expert advice and guidance on how to identify and diagnose FOP in their patients, current best practices for FOP management, and the most up-to-date information on novel therapies currently in clinical trial for treatment of FOP.

Educational Objectives:
This program is designed to address ACGME and NAM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

At the conclusion of this education, participants should be able to:
• Distinguish patients with FOP using the latest recommendations and criteria
• Develop effective FOP treatment plans which incorporate the most recent clinical evidence
• Evaluate the latest safety and efficacy data with FOP agents in late-stage development